8-K: Outlook Therapeutics Secures $172 Million in Funding, Advances ONS-5010 with FDA Agreement

Outlook Therapeutics has secured up to $172 million in funding and received FDA agreement on a key clinical trial protocol for its ONS-5010 drug.

Summary

• Outlook Therapeutics has received a Special Protocol Assessment (SPA) agreement from the FDA for its NORSE EIGHT clinical trial of ONS-5010 for wet AMD.
• The company has also secured up to $172 million in gross proceeds through private placements to fund the ONS-5010 program.
• The NORSE EIGHT trial is a non-inferiority study comparing ONS-5010 to ranibizumab, with a primary endpoint of mean change in BCVA from baseline to week 8.
• The company expects topline results from NORSE EIGHT and a BLA resubmission by the end of calendar year 2024.
• The private placement includes up to $60 million in gross proceeds at closing and an additional $99 million upon full cash exercise of warrants.
• The warrants have a feature that allows Outlook Therapeutics to require cash exercise if certain stock price and milestone conditions are met.
• Existing investors GMS Ventures and Syntone Ventures, along with directors, have agreed to vote in favor of the proposals required for the private placement.
• The company also reached an agreement to extend the maturity of its convertible promissory note to July 1, 2025, subject to certain conditions.

Sentiment

Score: 8

Explanation: The document is highly positive due to the SPA agreement with the FDA, the significant funding secured, and the clear path forward for ONS-5010. While there are risks, the overall tone is optimistic and suggests a strong likelihood of success.

Positives

• The SPA agreement with the FDA increases confidence in the ONS-5010 development program.
• The $172 million financing is expected to support the ONS-5010 development pathway through potential FDA approval and launch.
• The NORSE EIGHT trial is designed to address the clinical deficiency identified in the Complete Response Letter (CRL).
• The company has identified approaches to resolve the chemistry, manufacturing and controls comments in the CRL.
• The warrants include a feature that allows Outlook Therapeutics to require cash exercise if certain stock price and milestone conditions are met, potentially bringing in additional capital.
• The extension of the convertible note provides additional financial flexibility.

Negatives

• The private placement is subject to stockholder approval and other corporate actions.
• The company must still resolve chemistry, manufacturing and controls comments in the CRL.
• The company is dependent on the success of the NORSE EIGHT trial for BLA resubmission.

Risks

• The private placement is contingent on stockholder approval and other corporate actions.
• The company must successfully complete the NORSE EIGHT trial to address the clinical deficiency identified in the CRL.
• The company must resolve the chemistry, manufacturing and controls comments in the CRL.
• There is no guarantee that the FDA will approve the BLA for ONS-5010.
• The company is subject to risks associated with developing pharmaceutical product candidates and obtaining regulatory approvals.
• The company is subject to market conditions and future impacts related to macroeconomic factors.

Future Outlook

Outlook Therapeutics expects topline results from NORSE EIGHT and a BLA resubmission by the end of calendar year 2024. The company intends to use the net proceeds from the financings to fund its ONS-5010 clinical development programs, including to initiate and fund the planned NORSE EIGHT clinical trial, and for working capital and other general corporate purposes.

Management Comments

• The SPA increases our confidence that ONS-5010, if approved, will more effectively meet the needs of retina surgeons, patients and payers in the $9.5 billion ophthalmic anti-VEGF market in the United States.
• The financing represents a significant commitment by our new and existing stockholders to advance this important development program.
• We believe that the funds we expect to receive in this financing will position Outlook Therapeutics to support the ONS-5010 development pathway through potential FDA approval and launch.

Industry Context

This announcement is significant in the context of the ophthalmic anti-VEGF market, where there is currently no FDA-approved ophthalmic formulation of bevacizumab. If approved, ONS-5010 would provide a much-needed FDA-approved option for physicians currently using unapproved repackaged IV bevacizumab.

Comparison to Industry Standards

• The NORSE EIGHT trial design, a non-inferiority study comparing ONS-5010 to ranibizumab, is a common approach in the ophthalmic anti-VEGF space.
• The primary endpoint of mean change in BCVA from baseline to week 8 is a standard measure used in clinical trials for wet AMD.
• The $172 million financing is a substantial amount for a company at this stage of development, indicating strong investor confidence.
• The inclusion of top-tier institutional investors and insiders in the private placement is a positive sign for the company's prospects.
• The strategic commercialization agreement with Cencora is a common approach for biopharmaceutical companies to expand their reach and prepare for commercial launch.

Related Party Transactions

• GMS Ventures and Syntone Ventures, Outlook Therapeutics largest stockholders, as well as its directors, have entered into support agreements pursuant to which they have agreed to vote in favor of the proposals required for the private placement.
• GMS Ventures has committed to purchase Shares and Warrants for an aggregate purchase price of approximately $16.1 million.
• Syntone Ventures has committed to purchase the Syntone Shares and Syntone Warrants for an aggregate purchase price of approximately $5 million.

Stakeholder Impact

• Shareholders: The financing and SPA agreement are positive developments that could increase the value of the company.
• Employees: The funding provides job security and resources to advance the ONS-5010 program.
• Patients: If approved, ONS-5010 would provide a much-needed FDA-approved treatment option for wet AMD.
• Creditors: The extension of the convertible note provides additional financial stability.

Next Steps

• Commence the NORSE EIGHT clinical trial in the first quarter of CY2024.
• Obtain stockholder approval for the private placement and related corporate actions.
• Resolve the chemistry, manufacturing and controls comments in the CRL.
• Resubmit the BLA for ONS-5010 by the end of calendar year 2024.
• Prepare for potential commercial launch of ONS-5010.

Key Dates

Keywords

ONS-5010, bevacizumab, wet AMD, NORSE EIGHT, clinical trial, FDA, Biologics License Application, private placement, warrants, retinal diseases, financing, Special Protocol Assessment, convertible note